As touchHAEMATOLOGY approaches 20 years of providing education for busy haematologists, we are looking to the future—and it certainly looks bright!

At #EHA2025, Dr Shaji Kumar presented encouraging results from a phase II trial of teclistamab and talquetamab in extramedullary multiple myeloma. The bispecific combination achieved an 80% response rate and 55% complete responses, offering a promising new option for this aggressive, high-risk disease with limited treatment success to date.

Daisy Diaz Rohena discusses mechanisms of resistance in high-risk chronic lymphocytic leukemia (CLL), highlighting how relapsed cells maintain BCL2 dependence while upregulating BCL-XL. Her research supports dual targeting as a potential strategy, with WH25244 – a selective BCL-XL degrader – showing preclinical promise. She shares optimism for upcoming translational CLL studies at EHA 2025.

At #EHA2025, Dr Gurbaksh Kaur presented updated results from the iMMagine-1 trial of AnitoCell, a BCMA-targeted CAR T therapy. With a 97% response rate and manageable safety, the D-domain construct shows early promise in relapsed/refractory myeloma. Kaur discusses efficacy, neurotoxicity, sequencing questions and where the field is headed next.

In a study presented at #EHA2025, Dr Ferran Nadeau and colleagues reveal that multiclonality in CLL may be more pervasive – and older – than previously thought. Using single cell sequencing, they identify minor clones carrying CLL-like features and driver mutations decades before diagnosis, suggesting new opportunities for early detection.

Diffuse large B cell lymphoma is now understood to consist of multiple molecular subtypes, each with distinct biology and treatment responses. Dr Dan Hodson emphasises the need for standardised genomic profiling in clinical trials to guide subtype-specific therapies and bridge the current disconnect between research findings and clinical application.

Dr Eleni Gavriilaki, Assistant Professor of Hematology in Thessaloniki, reflects on the formative experiences and mentors that shaped her path. A touchHAEMATOLOGY Future Leader 2025, she discusses trust, clinical trials and the emotional complexity of care – and offers honest advice to the next generation of hematologists.

Dr Marlies Vanden Bempt, touchHAEMATOLOGY Future Leader 2025, reflects on her journey in haematology, the impact of mentorship, and her hopes for the future of the field. Now launching her own lab, she shares how calm leadership, resilience in research and openness to AI are shaping her vision for the next decade.

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.